type
These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR   <   60   mL/min/1.73   m(2) , suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population.